Results 21 to 30 of about 5,124 (246)
Future Science OA, 2021 Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.
Eran Kalmanovich +12 more
doaj +2 more sources
Use of idarucizumab for emergency surgery in patients taking dabigatran
Атеротромбоз, 2022 This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova +5 more
doaj +2 more sources
Turkish Journal of Emergency Medicine, 2020 Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial ...
Gorana Vukorepa +4 more
doaj +3 more sources
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +4 more sources
Bleeding Risk of Anticoagulation Reversal Strategies Before Heart Transplantation: A Retrospective Comparative Cohort Study [PDF]
Journal of Cardiovascular Development and DiseaseHeart transplantation (HT) poses high bleeding risks, especially for patients on anticoagulation. This study evaluates the use of idarucizumab for dabigatran (DBG) reversal compared to vitamin K antagonist (VKA) strategies in HT. A retrospective analysis
Antonio Prieto-Romero +10 more
doaj +2 more sources
Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile [PDF]
Cost Effectiveness and Resource AllocationBackground Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot +5 more
doaj +2 more sources
Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report [PDF]
International Journal of Emergency MedicineDabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli +5 more
doaj +2 more sources
PLoS ONE, 2019 BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke +7 more
doaj +3 more sources
Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases [PDF]
Research and Practice in Thrombosis and Haemostasis, 2023 Sophie Melicine +7 more
openalex +2 more sources